Mitral and Mitro-Aortic Valve Replacement with Sorin Bicarbon Valves Compared with St. Jude Medical Valves

Abstract

Objective:

We assessed the clinical results of two bileaflet mechanical valves: the St. Jude Medical (SJM) and the Sorin Bicarbon (Sorin Bicarbon) used either in single mitral valve replacement (MVR) or in double, aortic and mitral, valve replacement (DVR).

Methods:

Between September 1990 and November 1995, 217 patients received either a St. Jude Medical (n = 134) or a Sorin Bicarbon (n = 86): 136 mitral valve replacement with 83 St. Jude Medical and 53 Sorin Bicarbon and 84 double valve replacement with 51 St. Jude Medical and 33 Sorin Bicarbon. There was no difference between both St. Jude Medical and Sorin Bicarbon cohorts in respect of mitral valve physiopathology, etiology of valve disease, associated lesions, echocardiographic and hemodynamic data. The only significant preoperative difference was the age of patients within the double valve replacement group and the size of implanted valves within the mitral valve replacement group. Follow-up was 100% complete with a mean of 39±18 months, ranging between 6 and 68 months. The total follow-up was 657 patient-years (pt-y): 396 pt-y in the mitral valve replacement group and 274 pt-y in the double valve replacement group.

Results:

Hospital mortality (St. Jude Medical: 2.2%; Sorin Bicarbon: 6.9%) and late mortality (St. Jude Medical: 8.4%; Sorin Bicarbon: 6.3%) were not significantly different. Ten deaths were considered valve-related (St. Jude Medical 6, Sorin Bicarbon 4). The estimated 4-yr overall survival, including hospital mortality, was for St. Jude Medical-mitral valve replacement: 89±4% and St. Jude Medical-double valve replacement: 93±4%, and for Sorin Bicarbon-mitral valve replacement: 87±5% and Sorin Bicarbon-double valve replacement: 91±5%. The linearized incidence (% per pt-y) of valve-related complications was 6.39 in the St. Jude Medical cohort and 9.2 in the Sorin Bicarbon cohort. The linearized incidence (% pt-y) of the prevalent complication, valve thromboembolism and bleeding, was for St. Jude Medical-mitral valve replacement: 3.41, St. Jude Medical-double valve replacement: 3.16 and for Sorin Bicarbon-mitral valve replacement: 2.17 and Sorin Bicarbon-double valve replacement: 3.67. The differences between each group of an estimated 4-yr freedom from combined thromboembolism and bleeding were not significant (St. Jude Medical-mitral valve replacement: 90±4%, St. Jude Medical-double valve replacement: 84±6%, and for Sorin Bicarbon-mitral valve replacement: 94±3% and Sorin Bicarbon-double valve replacement: 75±17%).

Conclusions:

In this clinical non-randomized study, there was no evidence of any significant difference between St. Jude Medical and Sorin Bicarbon valves over a 4-yr follow-up.